effect overlay
activetrials
Dementia
Dementia
XanaMIA

A Phase 2b, Double-Blind, Placebo-Controlled, Parallel-Groups, 36-Week, 2-Arm Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® 10 mg daily in Patients with Mild or Moderate Dementia due to Alzheimer's Disease

HREC: 2024.032
Principal Investigator: A/Prof David Darby
Coordinator contact: Lesley-Anne Attard
Funding: Commercial
Active Trials - Other
Neurophysiology
Myasthenia Gravis Health Economic Modelling

An investigator-initiated national prospective health economics study to optimise the use of immunoglobulin treatment in adults with Myasthenia Gravis

HREC: 2024.022
Principal Investigator: Dr Belinda Cruse
Coordinator contact:
Funding: Non-Commercial
Placeholder
Neuropsychology
IONIS

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION717 in Patients with Prion Disease ION717-CS2

HREC: 2024.010
Principal Investigator: Prof Dennis Velakoulis
Coordinator contact: Anice Abin
Funding: Commercial
Dementia
Dementia
AusCADASIL

An Australian Cohort of CADASIL

HREC: 2023.213
Principal Investigator: Prof Amy Brodtmann
Coordinator contact: Dr Ashley Park
Funding: Non-Commercial
Stroke
Stroke
REVIVE

A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke who are not eligible for tissue plasminogen activator or thrombectomy

HREC: 2023.197
Principal Investigator: Prof Bruce Campbell
Coordinator contact: Christine Shin
Funding: Commercial